Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Prolia and osteonecrosis?What's the advised delay for milk post lipitor?Patent expiry trametinib?Bivalirudin manufacturer?Lipitor vs generics what's the price gap?
See the DrugPatentWatch profile for vivitrol
No, Vivitrol (naltrexone extended-release injectable suspension) is contraindicated in patients with acute hepatitis or liver failure due to risks of hepatotoxicity.[1] The drug carries a boxed warning for this, as elevated liver enzymes have occurred in some patients, sometimes leading to liver injury.[2]
Vivitrol is metabolized by the liver, so moderate to severe hepatic impairment (Child-Pugh B or C) requires caution and dose monitoring. In clinical studies, patients with mild liver issues tolerated it, but data is limited for advanced cases. Doctors may check baseline liver function tests (LFTs) before starting and monitor every 1-3 months.[1][3]
Trials for alcohol and opioid dependence included patients with mild liver enzyme elevations, with no disproportionate hepatotoxicity signals. Post-marketing reports note rare cases of elevated bilirubin or transaminases, resolving after discontinuation. No large-scale studies exist specifically for moderate/severe liver disease.[2][4]
Avoid if you have active liver failure. Symptoms to watch: jaundice, dark urine, fatigue. FDA label advises against use in acute liver disease and close LFT monitoring otherwise.[1] Sources [1]: Vivitrol Prescribing Information (FDA) [2]: Vivitrol Boxed Warning Summary [3]: LiverTox Database on Naltrexone [4]: Vivitrol Clinical Pharmacology [5]: ASAM Guidelines on Alcohol/Opioid Use Disorder
Other Questions About Vivitrol :